MediWound (NASDAQ:MDWD) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $17.73 and traded as high as $18.67. MediWound shares last traded at $18.55, with a volume of 46,268 shares.

Analysts Set New Price Targets

MDWD has been the subject of several recent analyst reports. Wall Street Zen cut shares of MediWound from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Zacks Research cut shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, MediWound has a consensus rating of “Hold” and a consensus target price of $32.25.

MediWound Price Performance

The business’s 50 day moving average price is $17.73 and its 200 day moving average price is $18.77. The stock has a market capitalization of $205.72 million, a P/E ratio of -7.03 and a beta of 0.27.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.68). The business had revenue of $5.71 million for the quarter, compared to the consensus estimate of $5.68 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. As a group, analysts forecast that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of MediWound

Several large investors have recently added to or reduced their stakes in MDWD. Bank of New York Mellon Corp grew its position in MediWound by 14.8% during the first quarter. Bank of New York Mellon Corp now owns 18,357 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,370 shares during the period. ARK Investment Management LLC grew its position in MediWound by 6.7% during the first quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company’s stock valued at $1,660,000 after buying an additional 6,684 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in MediWound by 17.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 3,343 shares in the last quarter. Deutsche Bank AG boosted its position in shares of MediWound by 2,255.2% in the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 6,044 shares during the period. Finally, Nuveen LLC bought a new position in shares of MediWound in the first quarter worth approximately $168,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.